Cachexia News and Research

RSS

Cachexia is a condition which denotes the excessive loss of weight. It occurs because of the depletion of adipose tissue and muscle mass in people who are not trying to lose weight.

New research explains how tumors may impair ability of the liver to respond to caloric deprivation

One of the worst cruelties of lethal cancer is the phenomenon called wasting, or in medical terms, cachexia (pronounced ka-CHEX-ia), in which a patient seems literally to diminish in bodily terms as the cancer ravages one or more internal organs.

8 Nov 2016

Biologic drugs may help prevent progressive bone loss in patients with RA

A new review by the International Osteoporosis Foundation Chronic Inflammation and Bone Structure Working Group concludes that early and aggressive treatment of Rheumatoid Arthritis (RA) with biologic drugs, specifically biological disease-modifying anti-rheumatic drugs (DMARDs), may be most effective in halting progressive bone loss in patients with RA.

7 Nov 2016

New, practical tool may help doctors to easily diagnose cachexia in cancer patients

About one third of cancer patients die because of cachexia - an involuntary weight loss, characterized primarily by muscle wasting and metabolic changes, which cannot be addressed or treated solely with increased food intake.

7 Nov 2016

Leading experts in iron deficiency to participate in 3rd European Iron Academy meeting

The 3rd European Iron Academy (EIA) will take place on the 12th and 13th September 2016 in Berlin, Germany, and will bring together over 450 clinicians with an interest in iron deficiency.

From CSL Ltd 16 Sep 2016

Selective manipulation of enzyme can stop cancer cachexia

Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.

30 Aug 2016

Researchers discover new role of cellular signaling molecule involved in release of hunger hormone

Researchers at UT Southwestern Medical Center have identified a previously unknown role of a cellular signaling molecule involved in release of the "hunger hormone" ghrelin, a finding that could have implications for optimal treatment of children taking beta blockers.

23 Aug 2016

New gene therapeutic approach could save people suffering from muscle wasting disease

A discovery by Washington State University scientist Dan Rodgers and collaborator Paul Gregorevic could save millions of people suffering from muscle wasting disease.

27 Jul 2016

Why does appetite loss occur during illness? An interview with Prof. Conti and Prof. Francesconi

Appetite, as a word, come from the Latin appetitus, meaning "desire for.” Therefore, appetite can be defined as a pleasurable sensation or the desire to eat. This sensation is coordinated by several brain areas associated with reward processing such amygdala, hippocampus, ventral pallidum, nucleus accumbens and striatum, and others.

28 Jun 2016

Mitofusin 2 protein could serve as therapeutic target to ameliorate sarcopenia in older adults

One of the alterations that most affects the quality of life of the elderly is muscle wastage and the resulting loss of strength, a condition known as sarcopenia. At about 55 years old, people begin to lose muscle mass, this loss continues into old age, at which point it becomes critical.

22 Jun 2016

Scientists discover how immune system molecule hijacks brain circuit to reduce appetite during illness

Loss of appetite during illness is a common and potentially debilitating phenomenon--in cancer patients, especially, it can even shorten lifespan.

5 May 2016

Mouse-based study shows exercise decreases cancer incidence, slows tumor growth

When you're pounding along an icy pavement or sweating through a gym workout, you try to remind yourself of the many health benefits of exercise. Between gasps, you can say that a healthy, fit lifestyle helps prevents obesity, a worldwide problem of increasing magnitude that has been linked to cardiovascular disease and diabetes.

11 Apr 2016

Helsinn, Mundipharma sign distribution, license and supply agreements for anamorelin

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announce that they have entered into distribution, license and supply agreements with Mundipharma and its network of independent associated companies granting exclusive rights to anamorelin in Norway, Finland, Sweden, Denmark and Iceland.

16 Feb 2016

UofL researchers discover mechanism involved in skeletal muscle repair

Researchers at the University of Louisville have discovered a mechanism involved in skeletal muscle repair that may enable clinicians to boost the effectiveness of adult stem cell therapies for diseases such as muscular dystrophy.

1 Dec 2015

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.

30 Nov 2015

Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health. The experimental agent, known as AR-42 while in testing, was developed and tested in preclinical studies at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

25 Nov 2015

Researchers discover new gene that could be a potential therapeutic target for muscle wasting

It is estimated that half of all cancer patients suffer from a muscle wasting syndrome called cachexia. Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients. Currently, there is no approved treatment for muscle wasting but a new study from the Research Institute of the McGill University Health Centre and University of Alberta could be a game changer for patients, improving both quality of life and longevity.

15 Sep 2015

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, the Swiss Group focused on building quality cancer care, and BIAL - Portela & Ca. S.A., one of the largest Iberian pharmaceutical companies, today announce that they have entered into an agreement for the exclusive distribution and licence rights to Anamorelin in Spain, Portugal, Angola and Mozambique.

8 Sep 2015

Scientists decipher new molecular signaling path that prompts protein degradation in muscle

Patients in advanced states of myocardial insufficiency generally lose their muscle mass and muscle strength. Indeed a fact that until now has negatively impacted the clinical course of the disease and that has resulted in poor prognoses for patients. Such pathological muscle loss impacts the skeletal muscles in particular.

11 Aug 2015

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

The ProGas study results show that three methods of gastrostomy are equally good in terms of complications and survival in patients with amyotrophic lateral sclerosis.

4 Aug 2015

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

The ProGas study results show that three methods of gastrostomy are equally good in terms of complications and survival in patients with amyotrophic lateral sclerosis.

4 Jun 2015

Cachexia News and Research

Further Reading

New research explains how tumors may impair ability of the liver to respond to caloric deprivation

Biologic drugs may help prevent progressive bone loss in patients with RA

New, practical tool may help doctors to easily diagnose cachexia in cancer patients

Leading experts in iron deficiency to participate in 3rd European Iron Academy meeting

Selective manipulation of enzyme can stop cancer cachexia

Researchers discover new role of cellular signaling molecule involved in release of hunger hormone

New gene therapeutic approach could save people suffering from muscle wasting disease

Why does appetite loss occur during illness? An interview with Prof. Conti and Prof. Francesconi

Mitofusin 2 protein could serve as therapeutic target to ameliorate sarcopenia in older adults

Scientists discover how immune system molecule hijacks brain circuit to reduce appetite during illness

Mouse-based study shows exercise decreases cancer incidence, slows tumor growth

Helsinn, Mundipharma sign distribution, license and supply agreements for anamorelin

UofL researchers discover mechanism involved in skeletal muscle repair

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

Researchers discover new gene that could be a potential therapeutic target for muscle wasting

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Scientists decipher new molecular signaling path that prompts protein degradation in muscle

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News